2 Undervalued Growth Stocks That Could Double Your Wealth in 2022

Growth stocks such as Curaleaf and WELL Health are trading at a massive discount to consensus estimates.

| More on:
stocks rising

Image source: Getty Images

The last two weeks have reminded equity investors that stock market corrections and pullbacks are an integral part of the investing cycle. But a pullback should be viewed as a chance to purchase quality stocks at attractive multiples.

Here, we take a look at two undervalued growth stocks that have underperformed the broader markets in recent trading sessions but that should gain significant momentum if market sentiment improves.

Curaleaf Holdings

An integrated medical and wellness cannabis operator in the U.S., Curaleaf Holdings (CNSX:CURA) is valued at a market cap of $6.51 billion. In Q3 of 2021, Curaleaf reported revenue of US$317 million, an increase of 74% year over year. It also generated US$52 million in operating cash flow.

The company confirmed it remains on track to achieve revenue guidance between US$1.2 billion and US$1.3 billion in 2021, making Curaleaf one of the largest cannabis producers in the world.

It also explained strategic acquisitions remain a key pillar of long-term growth plans. Last October, Curaleaf closed the acquisition of Los Suenos Farms and a month later announced plans to acquire Tryke Companies. Tryke is a vertically integrated multi-state operator that will enable Curaleaf to gain traction in markets such as Nevada, Utah, and Arizona.

Company CEO Joe Bayern stated, “We expanded our scale and reach by strategically growing our retail and wholesale presence and significantly increasing our cultivation capacity both organically and, more recently, through M&A.”

In Q3 of 2021, Curaleaf expanded the number of wholesale accounts by 6% sequentially to 2,100 and is on track to add 275,000 square feet of flower canopy by end of 2021.

Last month, Curaleaf confirmed it closed the acquisition of Bloom Dispensaries, which is a vertically integrated single state cannabis operator in Arizona. Right now, Curaleaf’s retail footprint has reached 13 dispensaries in Arizona and surpassed 120 dispensaries in the United States.

Bloom reported sales of US$66 million in 2021 with an adjusted EBITDA margin of 40%. The acquisition was valued at US$211 million.

Analysts expect Curaleaf sales to touch US$2.1 billion in 2022 valuing the stock at a forward price-to-sales multiple of less than three. It is also forecast to report an adjusted profit in 2022, making it a top bet for growth and value investors. Analysts tracking the stock expect Curaleaf to surge over 150% in the next 12 months.

WELL Health Technologies

Another beaten-down growth stock you can buy right now is WELL Health Technologies (TSX:WELL). The company is valued at a market cap of $942 million, which is incredibly cheap given it’s poised to end 2021 at an annualized revenue run rate of $450 million. Further, its adjusted EBITDA run rate is also forecast at $100 million.

So, WELL stock is trading at a price-to-earnings multiple of just over two and it managed to increase patient visits by 121% year over year in the December quarter. Last year, WELL Health announced the big-ticket acquisition of CRH Medical, which delivered US$43 million in free cash flows in 2021.

WELL stock is down 50% from all-time highs and is trading at a discount of almost 200% compared to consensus estimates.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Upwards momentum
Energy Stocks

3 Canadian Stocks That Could be Huge Winners in the Next Decade and Beyond

Stocks like Canopy Growth, Blackberry, and Ballard Power are leading and redefining new multi-billion dollar industries.

Read more »

A cannabis plant grows.
Cannabis Stocks

Should You Invest in Canadian Cannabis Stocks Like Canopy Growth in September?

Canadian cannabis stocks, including Canopy Growth, remain high-risk bets for investors, despite trading 94% below all-time highs.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

ACB Stock: What’s Behind Aurora Cannabis’ Recent Surge?

More countries are legalizing marijuana. Should you buy ACB stock?

Read more »

data analytics, chart and graph icons with female hands typing on laptop in background
Cannabis Stocks

Got $5,000? 3 Stocks to Hold for the Next 20 Years

Long-term investors can consider buying shares of Dollarama and Curaleaf to generate market-beating gains in the next two decades.

Read more »

A cannabis plant grows.
Cannabis Stocks

Is Now the Time to Buy Cannabis Stocks?

These cannabis stocks are up 70% and 19% this month! Should Canadian investors hop on board?

Read more »

A cannabis plant grows.
Cannabis Stocks

Why I’m Considering Canopy Growth Stock For My RRSP

As the cannabis industry grows, adding Canopy Growth stock to my RRSP will give me access to massive upside.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock Jumps 20%: Here’s What Happened

Canopy Growth stock (TSX:WEED)(NASDAQ:CGC) popped 20% on Monday from an announcement made by another cannabis producer.

Read more »

Retirement plan
Dividend Stocks

4 Stocks That Could Turn $100,000 Into $500,000 by the Time You Retire

Companies such as Brookfield Asset Management have the potential to consistently beat the broader markets and deliver stellar returns to…

Read more »